Business · 16/03/2021
FDA Reopens Comment Period for Orange Book Patent Information Listing
The FDA is reopening the comment period for a notice related to the listing of patent information in the Orange Book, a publication that tracks approved drugs, following the passage of the Orange Book Transparency Act in 2021.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →